Component

AREDS2 lutein/zeaxanthin addition to background AREDS formulation

AREDS2 lutein/zeaxanthin addition to background AREDS formulation. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Ten-year analysis by original L+Z assignment gave late-AMD HR 0.91 (95% CI 0.84–0.99).

    AREDS2 lutein/zeaxanthin addition to background AREDS formulation → Progression to late age-related macular degeneration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/lutein-research/35653117.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb", "start_char": 0, "end_char": 3155, "text_sha256": "66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb"}
    experimental_model
    Ten-year epidemiologic follow-up of randomized AREDS2 assignments
    exposure
    Original randomization followed by common AREDS2 supplementation for everyone
    limitations
    Not ten years of continuously separated randomized treatment; same cohort, additional follow-up.
    nutrient_topic
    Lutein research collection; topical membership is not evidence of a direct dietary effect. · Lutein
    organism
    3882 original participants
    plain_language
    A modest long-term association favored original assignment.
    primary_references
    [lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640
    tissue_or_cell_type
    Late AMD and lung cancer

    Lutein: metabolism, signaling and nutrient connections (2026-09-17) · lines 788–799

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Ten-year epidemiologic follow-up of randomized AREDS2 assignments · source_derived_draft · unverified_draft

    ### lutein-areds-longterm Ten-year analysis by original L+Z assignment gave late-AMD HR 0.91 (95% CI 0.84–0.99). Condition category: normal nutrient_topic: Lutein research collection; topical membership is not evidence of a direct dietary effect. plain_language: A modest long-term association favored original assignment. organism: 3882 original participants tissue_or_cell_type: Late AMD and lung cancer experimental_model: Ten-year epidemiologic follow-up of randomized AREDS2 assignments limitations: Not ten years of continuously separated randomized treatment; same cohort, additional follow-up. exposure: Original randomization followed by common AREDS2 supplementation for everyone evidence_span: {"source_cache": "artifacts/lutein-research/35653117.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb", "start_char": 0, "end_char": 3155, "text_sha256": "66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb"} [lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640
    Complete structured claim and evidence

  2. L+Z assignment had lung-cancer OR 1.15 (95% CI 0.79–1.66), without a significant increase.

    AREDS2 lutein/zeaxanthin addition to background AREDS formulation → Human lung cancer incidence source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/lutein-research/35653117.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb", "start_char": 0, "end_char": 3155, "text_sha256": "66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb"}
    experimental_model
    Ten-year epidemiologic follow-up of randomized AREDS2 assignments
    exposure
    Original randomization followed by common AREDS2 supplementation for everyone
    limitations
    Not ten years of continuously separated randomized treatment; same cohort, additional follow-up.
    nutrient_topic
    Lutein research collection; topical membership is not evidence of a direct dietary effect. · Lutein
    organism
    3882 original participants
    plain_language
    The beta-carotene signal was not demonstrated for the pair.
    primary_references
    [lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640
    tissue_or_cell_type
    Late AMD and lung cancer

    Lutein: metabolism, signaling and nutrient connections (2026-09-17) · lines 801–812

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Ten-year epidemiologic follow-up of randomized AREDS2 assignments · source_derived_draft · unverified_draft

    ### lutein-areds-longterm-lung-null L+Z assignment had lung-cancer OR 1.15 (95% CI 0.79–1.66), without a significant increase. Condition category: normal nutrient_topic: Lutein research collection; topical membership is not evidence of a direct dietary effect. plain_language: The beta-carotene signal was not demonstrated for the pair. organism: 3882 original participants tissue_or_cell_type: Late AMD and lung cancer experimental_model: Ten-year epidemiologic follow-up of randomized AREDS2 assignments limitations: Not ten years of continuously separated randomized treatment; same cohort, additional follow-up. exposure: Original randomization followed by common AREDS2 supplementation for everyone evidence_span: {"source_cache": "artifacts/lutein-research/35653117.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb", "start_char": 0, "end_char": 3155, "text_sha256": "66ae960c242e18fe246c623e055e94d52a638b6ac6330f8a85208a58d52c13cb"} [lutein-p35653117] Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. (2022). https://pubmed.ncbi.nlm.nih.gov/35653117/ DOI: 10.1001/jamaophthalmol.2022.1640
    Complete structured claim and evidence

  3. Primary L+Z versus placebo comparison gave HR 0.90 (98.7% CI 0.76–1.07; P=0.12).

    AREDS2 lutein/zeaxanthin addition to background AREDS formulation → Progression to late age-related macular degeneration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/lutein-research/23644932.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1bd379926e56d7243222c2ef69d6367b74aede2b02faabfb77fadcbadf95008f", "start_char": 0, "end_char": 3037, "text_sha256": "1bd379926e56d7243222c2ef69d6367b74aede2b02faabfb77fadcbadf95008f"}
    experimental_model
    AREDS2 phase 3 factorial randomized trial
    exposure
    Lutein 10 mg + zeaxanthin 2 mg daily; background AREDS formula; median five years
    limitations
    Combination and background treatment prevent attribution to lutein alone; primary contrast differs from replacement and main-effects analyses. Published correction 10.1001/jama.2013.6403 changes the Table 3 lung-neoplasm row label and Table 4 lung-neoplasm entries. These records use the indexed abstract and do not reproduce the uncorrected Table 4. Correction: https://jamanetwork.com/journals/jama/fullarticle/1710434 .
    nutrient_topic
    Lutein research collection; topical membership is not evidence of a direct dietary effect. · Lutein
    organism
    4203 adults aged 50–85 at elevated AMD progression risk
    plain_language
    Adding the pair did not meet the primary statistical threshold.
    primary_references
    [lutein-p23644932] Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. (2013). https://pubmed.ncbi.nlm.nih.gov/23644932/ DOI: 10.1001/jama.2013.4997
    tissue_or_cell_type
    Eyes with large drusen and/or fellow-eye advanced AMD

    Lutein: metabolism, signaling and nutrient connections (2026-09-17) · lines 723–734

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · AREDS2 phase 3 factorial randomized trial · source_derived_draft · unverified_draft

    ### lutein-areds-primary-null Primary L+Z versus placebo comparison gave HR 0.90 (98.7% CI 0.76–1.07; P=0.12). Condition category: normal nutrient_topic: Lutein research collection; topical membership is not evidence of a direct dietary effect. plain_language: Adding the pair did not meet the primary statistical threshold. organism: 4203 adults aged 50–85 at elevated AMD progression risk tissue_or_cell_type: Eyes with large drusen and/or fellow-eye advanced AMD experimental_model: AREDS2 phase 3 factorial randomized trial limitations: Combination and background treatment prevent attribution to lutein alone; primary contrast differs from replacement and main-effects analyses. Published correction 10.1001/jama.2013.6403 changes the Table 3 lung-neoplasm row label and Table 4 lung-neoplasm entries. These records use the indexed abstract and do not reproduce the uncorrected Table 4. Correction: https://jamanetwork.com/journals/jama/fullarticle/1710434 . exposure: Lutein 10 mg + zeaxanthin 2 mg daily; background AREDS formula; median five years evidence_span: {"source_cache": "artifacts/lutein-research/23644932.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1bd379926e56d7243222c2ef69d6367b74aede2b02faabfb77fadcbadf95008f", "start_char": 0, "end_char": 3037, "text_sha256": "1bd379926e56d7243222c2ef69d6367b74aede2b02faabfb77fadcbadf95008f"} [lutein-p23644932] Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. (2013). https://pubmed.ncbi.nlm.nih.gov/23644932/ DOI: 10.1001/jama.2013.4997
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards